IRIS
CHITI, ARTURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.031
AS - Asia 7.833
EU - Europa 3.291
SA - Sud America 1.271
AF - Africa 483
Continente sconosciuto - Info sul continente non disponibili 180
OC - Oceania 12
Totale 30.101
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.634
SG - Singapore 4.873
CN - Cina 1.241
BR - Brasile 1.037
DE - Germania 736
VN - Vietnam 734
IT - Italia 568
FI - Finlandia 552
IE - Irlanda 404
NG - Nigeria 349
CA - Canada 251
FR - Francia 235
IN - India 215
HK - Hong Kong 187
GB - Regno Unito 169
NL - Olanda 136
SE - Svezia 136
TR - Turchia 111
AR - Argentina 87
BD - Bangladesh 76
RU - Federazione Russa 75
MX - Messico 70
IQ - Iraq 66
IL - Israele 62
BE - Belgio 59
PL - Polonia 46
ZA - Sudafrica 39
ES - Italia 33
CL - Cile 31
EC - Ecuador 30
PK - Pakistan 29
ID - Indonesia 25
JP - Giappone 25
UA - Ucraina 25
CO - Colombia 24
VE - Venezuela 21
MA - Marocco 20
SA - Arabia Saudita 20
PH - Filippine 18
AE - Emirati Arabi Uniti 16
AT - Austria 16
JM - Giamaica 16
TN - Tunisia 16
KE - Kenya 15
PY - Paraguay 15
IR - Iran 14
KG - Kirghizistan 13
NP - Nepal 13
JO - Giordania 12
KZ - Kazakistan 12
NI - Nicaragua 12
PE - Perù 12
CZ - Repubblica Ceca 11
MY - Malesia 11
EG - Egitto 10
AZ - Azerbaigian 9
LT - Lituania 9
TW - Taiwan 9
UY - Uruguay 9
AU - Australia 8
ET - Etiopia 8
EU - Europa 8
RO - Romania 8
UZ - Uzbekistan 8
CH - Svizzera 7
DO - Repubblica Dominicana 7
HN - Honduras 7
PA - Panama 7
PT - Portogallo 7
BG - Bulgaria 6
CR - Costa Rica 6
DZ - Algeria 6
SV - El Salvador 6
EE - Estonia 5
GT - Guatemala 5
HR - Croazia 5
LB - Libano 5
MD - Moldavia 5
SN - Senegal 5
TT - Trinidad e Tobago 5
BY - Bielorussia 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
AO - Angola 3
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
GR - Grecia 3
KR - Corea 3
LV - Lettonia 3
MN - Mongolia 3
MT - Malta 3
OM - Oman 3
PS - Palestinian Territory 3
RS - Serbia 3
AM - Armenia 2
BH - Bahrain 2
Totale 29.896
Salva come PNG Salva come JPEG
Città #
Singapore 2.296
Dallas 2.246
Wilmington 2.014
Chandler 1.882
Ashburn 989
San Mateo 776
The Dalles 728
Ann Arbor 609
Helsinki 547
San Jose 545
Shanghai 533
Falkenstein 448
Council Bluffs 404
Dublin 401
Leawood 401
Boardman 357
Benin City 348
Princeton 331
Lawrence 327
Beijing 311
New York 293
Ho Chi Minh City 253
Milan 228
Fairfield 195
Toronto 183
Woodbridge 183
Paris 169
Hanoi 167
Hong Kong 152
Santa Clara 144
Los Angeles 137
Amsterdam 118
Pune 99
London 94
São Paulo 88
Kocaeli 80
Seattle 79
Buffalo 70
Rome 69
San Diego 63
Brussels 57
Phoenix 57
Norwalk 50
Da Nang 48
Monmouth Junction 44
Rio de Janeiro 44
Brooklyn 41
Warsaw 40
Munich 35
Houston 33
Moscow 33
Orem 32
Chicago 30
Falls Church 30
Hillsboro 25
Chennai 24
Haiphong 24
Belo Horizonte 23
Johannesburg 23
Miami 23
Montreal 23
Naples 21
Atlanta 20
San Francisco 20
Baghdad 19
Mexico City 19
Campinas 18
Figino 18
Philadelphia 18
Hải Dương 17
Redmond 17
Cincinnati 16
Dhaka 16
Mumbai 16
Tokyo 16
Bến Tre 15
Queens 15
Stockholm 15
Boston 14
Brasília 14
Charlotte 14
Curitiba 14
Denver 14
Redwood City 14
Santiago 14
Goiânia 13
Guayaquil 13
Osasco 13
Porto Alegre 13
Frankfurt am Main 12
Nairobi 12
Pittsburgh 12
Sacramento 12
Turin 12
Bishkek 11
Cambridge 11
Columbus 11
Des Moines 11
Erbil 11
Guarulhos 11
Totale 20.668
Salva come PNG Salva come JPEG
Nome #
11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. 762
111In-octreotide uptake in granulomatous and tumor lesions in a patient with small-cell lung cancer 725
111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer. 701
11Cl-choline PET/CT in imaging locally advanced prostate cancer 684
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 159
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 155
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 146
Ga-68-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study 140
68GA-PSMA PET/CT FOR PRIMARY DIAGNOSIS OF PROSTATE CANCER IN MEN WITH CONTRAINDICATIONS TO OR NEGATIVE MRI: A PROSPECTIVE OBSERVATIONAL STUDY 133
Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions 130
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 130
Applications of PET imaging with radiolabelled choline (C-11/F-18-choline) 126
A portrait of the scientist as a young woman Comments after the first EANM Young Investigators' Meeting 124
arallel comparison of 68Ga-Prostate Specific Membrane Antigen PET-CT and PRIMUS in primary prostate cancer diagnosis 124
[F-18] FDG PET/CT features for the molecular characterization of primary breast tumors 124
A case of metastatic axillary lymph nodes involvement from unknown primary cancer: Clinical usefulness of [Tc-99m]-sestamibi 121
Positron Emission Tomography-Computed Tomography for Patients with Recurrent Colorectal Liver Metastases: Impact on Restaging and Treatment Planning 121
Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart Involvement 120
F-18-DOPA PET/CT in Neuroblastoma Comparison of Conventional Imaging With CT/MR 120
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy 118
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 118
Procedure guidelines for PET/CT tumour imaging with Ga-68-DOTA-conjugated peptides: Ga-68-DOTA-TOC, Ga-68-DOTA-NOC, Ga-68-DOTA-TATE 117
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 117
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant 113
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 112
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 112
I-131/I-123-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging 109
Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer: Can positron emission tomography (PET) with F-18-FDG be considered as the best method? 108
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 108
Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery 107
A DOUBTFUL IMAGE OF LEVEEN SHUNT PATENCY 107
[18F]FDG PET/CT in Large Vessel Vasculitis: The Impact of Expertise and Confounders on Image Analysis 106
INDIUM-111-DTPA-OCTREOTIDE SCINTIGRAPHY MODULATION BY TREATMENT WITH UNLABELED SOMATOSTATIN ANALOG IN SMALL-CELL LUNG-CANCER 106
Role of I-131-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours - Experience of the National Cancer Institute of Milan 106
A risk management approach for imaging biomarker-driven clinical trials in oncology 106
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography 106
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 106
Diffusion-weighted imaging and loco-regional N staging of patients with colorectal liver metastases 104
Ga-68-PSMA PET/CT for primary diagnosis of prostate cancer in men with contraindications to or negative mpMRI 104
Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals 103
A case of atypical giant cell arteritis diagnosed by positron emission tomography (PET) 103
[C-11] Choline PET/CT Impacts Treatment Decision Making in Patients With Prostate Cancer Referred for Radiotherapy 103
Targeted PET/TRUS software fusion‑guided biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy: A feasibility study and preliminary results 100
Exploration of Disease Markers under Translational Medicine Model 99
Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer 99
Application of Convolutional Neural Networks is promising in the definition of T-stage in lung cancer 99
Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma 99
Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-68-DOTA-conjugated somatostatin receptor targeting peptides and F-18-DOPA 97
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery 97
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [F-18]fluorodeoxyglucose 96
[F-18]FDG PET/CT in non-union: improving the diagnostic performances by using both PET and CT criteria 96
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 96
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 96
Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma 96
C-11-Methionine uptake in secondary brain epilepsy 95
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems 95
Baseline FDG-PET/CT Radiomics to Predict Outcome in Lung Cancer Patients Treated with Surgery 95
C-11-labeled methionine and evaluation of malignant pleural mesothelioma 94
Role of C-11-choline PET/CT in radiation therapy planning of patients with prostate cancer 94
PRELIMINARY-RESULTS OF PREOPERATIVE AXILLARY RADIOIMMUNOSCINTIGRAPHY WITH IN-111 B72.3 IN BREAST-CANCER 94
PET/CT radiomics in breast cancer: Mind the step 94
Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail 93
Assessment of mediastinal involvement in lung cancer with technetium-99m-sestamibi SPECT 93
FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables 93
Assessment of tumor response in malignant pleural mesothelioma 93
Bone lesion in a patient with transplanted liver for a metastatic carcinoid. The role of somatostatin receptor scintigraphy 93
A method to reduce acetonitrile amount in F-18-FDG synthesis 93
Chest CT in patients with a moderate or high pretest probability of COVID-19 and negative swab 93
The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine 92
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 92
Utility of gallium-67 in determining the radicality of lymph node dissections of the neck for metastatic lymph nodes with extranodal spread in patients affected by carcinoma of the head and neck 92
Prone scintimammography in patients with non-palpable breast lesions 92
Key elements of preparedness for pandemic coronavirus disease 2019 (COVID-19) in nuclear medicine units 92
Convolutional Neural Networks Promising in Lung Cancer T-Parameter Assessment on Baseline FDG-PET/CT 91
PREDICTIVE VALUE OF EARLY PET DURING SALVAGE CHEMOTHERAPY IN RELAPSING/REFRACTORY HODGKIN'S LYMPHOMA (HL) PATIENTS 91
Value of FDG-PET/CT radiomic features in predicting response to anti-programmed death 1 (PD-1) antibodies treatment in refractory Hodgkin Lymphoma patients 91
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma 91
Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review 91
48P The relationship among bowel FDG-PET uptake, pathological complete response, and the influence of eating and exercise habits in breast cancer patients undergoing neoadjuvant chemotherapy 90
The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians 90
PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014 90
F-18-FDG PET/CT scans for children and adolescents 90
Prognostic significance of molecular and imaging biomarkers in primary brain tumors 90
Prospective evaluation of Ga-68-PSMA PET/CT in primary prostate cancer diagnosis - final results of a dedicated trial 90
PET/CT with C-11-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data 90
[18F]FDG-PET/CT Texture Analysis in “Hot” Thyroid Nodules: Results of the validation Cohort 90
Evaluation of response: is F-18-FDG PET the answer? 89
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 89
Texture analysis and machine learning to characterize suspected thyroid nodules and differentiated thyroid cancer: Where do we stand? 89
Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate 89
Radiomics of Liver Metastases: A Systematic Review 89
Nuclear medicine imaging of neuroendocrine tumours 88
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 88
Axillary node metastasis detection in breast cancer with Tc-99m-sestamibi and In-111-pentetreotide 88
Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion 87
Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol 2011;59:572-83 87
New Clinical Indications for F-18/C-11-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature 87
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 87
Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma 87
Comments on the Italian Society of Endocrinology recommendations on post-surgical thyroid ablation in differentiated thyroid cancer 86
Totale 12.691
Salva come PNG Salva come JPEG
Categoria #
all - tutte 190.314
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 190.314
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.758 0 17 62 414 37 28 73 260 161 129 486 91
2022/20235.106 748 197 462 560 456 462 10 410 947 432 344 78
2023/20242.627 220 320 583 174 63 301 150 129 51 35 240 361
2024/20253.436 90 71 28 42 62 431 195 380 435 888 414 400
2025/202611.654 1.383 759 1.977 918 281 431 2.914 979 550 533 317 612
2026/20271.450 624 826 0 0 0 0 0 0 0 0 0 0
Totale 30.101